Who are AScVS + Prazosin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LI, HyperAcute-Pancreas Immunotherapy, IMM-101.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ascvs-prazosin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

AScVS + Prazosin — Competitive Intelligence Brief

AScVS + Prazosin (AScVS + Prazosin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cancer immunotherapy vaccine. Area: Oncology.

phase 3 Cancer immunotherapy vaccine Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AScVS + Prazosin (AScVS + Prazosin) — Haffkine Bio-Pharmaceutical Corporation Ltd.. AScVS is an autologous stem cell vaccine that stimulates immune responses against cancer, combined with prazosin, an alpha-1 adrenergic antagonist that may enhance immune function.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AScVS + Prazosin TARGET	AScVS + Prazosin	Haffkine Bio-Pharmaceutical Corporation Ltd.	phase 3	Cancer immunotherapy vaccine
LI	LI	CEL-SCI Corporation	marketed	Cancer immunotherapy vaccine
HyperAcute-Pancreas Immunotherapy	HyperAcute-Pancreas Immunotherapy	NewLink Genetics Corporation	phase 3	Cancer immunotherapy vaccine combination	Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway
IMM-101	IMM-101	Immodulon Therapeutics Ltd	phase 3	Cancer immunotherapy vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cancer immunotherapy vaccine class)

CEL-SCI Corporation · 1 drug in this class
Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
Immodulon Therapeutics Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AScVS + Prazosin — Competitive Intelligence Brief. https://druglandscape.com/ci/ascvs-prazosin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab